Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target
about
The emerging roles of exosomes in leukemogeneisUpdate on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesLong-term intravenous administration of carboxylated single-walled carbon nanotubes induces persistent accumulation in the lungs and pulmonary fibrosis via the nuclear factor-kappa B pathwayCooperative down-regulation of ribosomal protein L10 and NF-κB signaling pathway is responsible for the anti-proliferative effects by DMAPT in pancreatic cancer cellsAberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia.Aberrant AML1 gene expression in the diagnosis of childhood leukemias not characterized by AML1-involved cytogenetic abnormalities.Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive LeukemiasOxidative Stress and Carcinogenesis: Potential of Phytochemicals in Breast Cancer Therapy.Targeting acute myeloid leukemia stem cell signaling by natural products.Genetic polymorphisms of IL-18 rs1946518 and IL-1β rs16944 are associated with prognosis and survival of acute myeloid leukemia.Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer.Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.Identification of potential tissue-specific cancer biomarkers and development of cancer versus normal genomic classifiers.The Regulation of Pathways of Inflammation and Resolution in Immune Cells and Cancer Stem Cells by Selenium.Dihydromyricetin induces apoptosis and cytoprotective autophagy through ROS-NF-κB signalling in human melanoma cells.X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery.Lp16-PSP, a Member of YjgF/YER057c/UK114 Protein Family Induces Apoptosis and p21WAF1/CIP1 Mediated G1 Cell Cycle Arrest in Human Acute Promyelocytic Leukemia (APL) HL-60 Cells.(Immuno)proteasomes as therapeutic target in acute leukemia.Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.Heteronemin, a marine natural product, sensitizes acute myeloid leukemia cells towards cytarabine chemotherapy by regulating farnesylation of Ras.Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.NF-κB promotes the stem-like properties of leukemia cells by activation of LIN28B.
P2860
Q26748606-57B36219-8D3E-4410-BF4D-0737D30F6F03Q28071384-A715C1A9-3220-4FF1-B13D-412C8E28894DQ29247884-D8FDE666-FB6B-4283-A57A-6F0D26A2EF11Q33798706-E0316E45-6B8F-429A-952E-7A5730FFFDA8Q34047994-D0071B84-F70E-40A0-9E87-F7F703F1AC50Q38710144-4C41EB72-7F35-4483-9EEF-24E43DB5E409Q38855013-D0F63A3F-963E-448C-A96F-FA84276B6C79Q38937733-BCD7BA04-7B34-4817-A03A-2C3C1D7D24BCQ39095124-591948EC-0037-479A-9FEE-2B67C737E55FQ39109921-5C1B4238-3701-456C-9827-A5AF8EA539A5Q40436275-01A1F649-E70B-4E87-BB93-DF05BB2DA3E2Q42121084-B7F1896C-23CE-481B-80A4-4CFD4DBD1DAAQ44176860-343F38DE-D75F-4065-992B-4B09C88D0227Q45943755-BD284BEA-7E03-409A-96F6-633A2FDD7743Q46279053-C6000EBC-5328-4A6C-B781-472056ABBD91Q46369644-88614955-4147-4551-9296-8E8E6F75B185Q47103190-98616931-CB96-4263-9462-DFADFBE15CB5Q47107765-2F5547A2-DCDC-4AB8-A377-FAF6D11122FAQ47131929-CD319829-0A5A-4F94-B153-C5AE902233CEQ51747038-0A1D339F-DD70-4C1D-BCF9-FB27FCDD5434Q52668830-9107844F-BC54-4201-926F-12A5520A8776Q52714610-2B4AACB5-3AAA-44D4-A65C-21D0F3F543BAQ54917620-B5704A8D-16A2-4ACD-BEE9-FBBF6F3433EFQ55119833-CF187DC1-3715-4AD0-8253-0626BD8580AF
P2860
Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Aberrant nuclear factor-kappa ...... ogenesis to therapeutic target
@ast
Aberrant nuclear factor-kappa ...... ogenesis to therapeutic target
@en
Aberrant nuclear factor-kappa ...... ogenesis to therapeutic target
@nl
type
label
Aberrant nuclear factor-kappa ...... ogenesis to therapeutic target
@ast
Aberrant nuclear factor-kappa ...... ogenesis to therapeutic target
@en
Aberrant nuclear factor-kappa ...... ogenesis to therapeutic target
@nl
prefLabel
Aberrant nuclear factor-kappa ...... ogenesis to therapeutic target
@ast
Aberrant nuclear factor-kappa ...... ogenesis to therapeutic target
@en
Aberrant nuclear factor-kappa ...... ogenesis to therapeutic target
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Aberrant nuclear factor-kappa ...... ogenesis to therapeutic target
@en
P2093
Jianbiao Zhou
Wee-Joo Chng
Ying Qing Ching
P2860
P304
P3181
P356
10.18632/ONCOTARGET.3545
P407
P5008
P577
2015-03-20T00:00:00Z